Crescent Biopharma Inc.(CBIO:US)
Market Cap$328.67M
Key Metrics
Price$11.84
Revenue (TTM)$11.88M
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$165.12M
EBITDA (TTM)-$162.91M
Op. Margin (TTM)-1.42K%
Dividend Yield-
Holders Yield-
Cash on hand$171.59M
Total Assets$182.76M
Net Assets$163.26M
Total Debt$1.44M
Key Metrics
Price$11.84
Revenue (TTM)$11.88M
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$165.12M
EBITDA (TTM)-$162.91M
Op. Margin (TTM)-1.42K%
Dividend Yield-
Holders Yield-
Cash on hand$171.59M
Total Assets$182.76M
Net Assets$163.26M
Total Debt$1.44M
Financials
| Name | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $1.04M | $10.84M | $0 | - | - | $0 | $0 | $0 | $0 | $0 |
Cost of Revenue | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 |
Gross Profit | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 |
| $26.36M | $25.77M | $102.34M | $25.89M | - | - | $17.19M | $1.62M | $2.54M | $4.56M | $4.83M | |
| Research and Development | $19.39M | $17.9M | $95.03M | $20.35M | - | - | $14.03M | $415K | $318K | $588K | $660K |
| Selling, General, and Administrative | $8.74M | $7.87M | $7.31M | $5.54M | - | - | $3.16M | $2.41M | $2.23M | $3.97M | $4.17M |
| Other Operating Expenses | -$1.77M | - | - | - | - | - | - | -$1.2M | - | - | - |
Operating Income | -$26.36M | -$24.73M | -$91.49M | -$25.89M | - | - | -$17.19M | -$1.62M | -$2.54M | -$4.56M | -$4.83M |
| $1.53M | $1.45M | $1.1M | $1.28M | $313K | $188K | -$676K | $47K | $73K | $4.83M | -$35.28M | |
| Non-Operating Interest Income | $1.53M | $1.45M | $1.1M | $1.28M | $313K | $188K | $176K | $47K | $73K | $96K | $167K |
| Non-Operating Interest Expense | $0 | $0 | $0 | $0 | - | - | $852K | - | - | - | - |
| Other Income/Expense | - | - | - | - | - | - | - | - | - | $4.74M | -$35.45M |
Income Before Tax | -$24.84M | -$23.28M | -$90.4M | -$24.61M | - | - | -$17.87M | -$1.58M | -$2.47M | $274K | -$40.11M |
Income Tax | - | - | - | - | - | - | $0 | $0 | $2K | $14K | - |
Net Income | -$24.84M | -$23.28M | -$92.4M | -$24.61M | - | - | -$17.87M | -$1.58M | -$2.47M | $260K | -$40.45M |
Minority Interests | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -$24.84M | -$23.28M | -$92.4M | -$24.61M | - | - | -$17.87M | -$1.58M | -$2.47M | $260K | -$40.45M |
Shares Outstanding (Basic) | 30.53M | 30.4M | 20.17M | 16.54M | 3.86M | - | 19.5M | 37.98M | 37.8M | 37.76M | 31.76M |
Shares Outstanding (Diluted) | 30.53M | 30.4M | 20.17M | 16.54M | 3.86M | - | 19.5M | 37.98M | 37.8M | 37.98M | 31.76M |
EPS (Basic) | -$0.74 | -$0.70 | -$4.01 | -$1.27 | -$4.93 | - | -$0.92 | -$0.04 | -$0.07 | $0.01 | -$1.28 |
EPS (Diluted) | -$0.74 | -$0.70 | -$4.01 | -$1.27 | -$4.93 | - | -$0.92 | -$0.04 | -$0.07 | $0.01 | -$1.28 |
EBIT | -$24.84M | -$23.28M | -$90.4M | -$24.61M | - | - | -$17.02M | -$1.62M | -$2.54M | -$4.56M | -$62.62M |
EBITDA | -$24.77M | -$23.22M | -$90.34M | -$24.58M | - | - | -$17.02M | -$1.62M | -$2.54M | -$9.29M | -$27.34M |